Knowledge Centre · Marketing authorisation

Marketing authorisation transfer: the renewal requirement, open variations and the transition period

Melvin International Consulting9 min read

A marketing authorisation (MA) transfer is the process by which responsibility for a product passes in full to a new MA holder (MAH) while the product stays on the market. Since an amendment in December 2024, MAs that have not completed their renewal can no longer be transferred. In this article we summarise the regulatory framework for transfers, what TİTCK looks at, the relevant time limits and the transition period after the transfer.

When does an MA transfer come into play?

Under Article 26 of the Regulation on the Marketing Authorisation of Human Medicinal Products, the MA of any human medicinal product authorised by TİTCK may be transferred. The transfer can be based on one of three instruments:

  • A transfer agreement between the parties executed before a notary
  • A court judgment establishing that the MA has been transferred
  • A decision of the enforcement office that the MA has been sold through compulsory enforcement

The Regulation also covers three special situations. Where a licensor changes its representative in Türkiye, additional document requirements apply. MAs suspended after a cancellation process started at the MAH’s request, and announced on TİTCK’s website, may be transferred, with the MAH’s consent and subject to the transfer conditions, to applicants who undertake to place the product on the market; cancellation does not proceed for MAs subject to a transfer application (Art. 23/5). Rights arising from a pending MA application may also be transferred under the same conditions (Art. 27).

What does TİTCK look at in a transfer application?

TİTCK’s review covers not only whether the transfer is legally valid but also whether the transferee can carry the responsibilities expected of an MAH. The documents listed in the Regulation fall under these headings:

  • Transfer document: A record showing the product name, MA date and number and the parties’ details, and confirming that the complete, up-to-date dossier approved by TİTCK has been handed over to the transferee in full
  • Transferee’s eligibility: Evidence that the applicant belongs to a profession entitled to apply for an MA, the Turkish Trade Registry Gazette showing the responsible persons, and documents on the pharmacovigilance officer and the scientific service
  • Product information: Updated SmPC and PIL with inner and outer packaging samples or, if these cannot be provided, an undertaking that the necessary updates will be made after the transfer
  • Manufacturing: Evidence that the manufacturing sites in the MA operate in line with GMP, and a Manufacturing Site Authorisation for active substance manufacturing sites in Türkiye
  • Depending on the product’s status: A licensor authorisation for imported or licensed products, a contract manufacturing agreement for contract manufacturing, and a co-marketing agreement for co-marketed products
  • Packaging and barcodes: Inner and outer packaging drafts for all pack sizes, and barcodes registered to the transferee’s name and address

TİTCK’s Guideline on Cases Requiring the Re-issue of a Marketing Authorisation (İRD-KLVZ-23) adds documents such as a manufacturing site flow chart, the MA fee receipt and a table of transfer application details. The Guideline also lists cases in which a transfer cannot be made. A transfer is not possible while the product is under attachment, although it can proceed if the enforcement office’s permission and the creditors’ consent are submitted under Article 86 of the Enforcement and Bankruptcy Law. A transfer does not go ahead if the transferee already holds an MA for a product with the same strength, pharmaceutical form and indication, and allergen products with temporary authorisation cannot be transferred. If the transferee has a product with the same active substance under a different name, a name change may also be needed under the naming rules.

Since the May 2023 amendment, the GMP certificate and the active substance Manufacturing Site Authorisation requirements are also grounds for suspending the MA (Art. 22/1-ö). A missing document therefore does not just delay the application; it puts the MA itself at risk.

Can an MA that has not been renewed be transferred?

No. The sixth paragraph added to Article 26 by the amendment of 3 December 2024 is explicit: no transfer is made for human medicinal products whose MA renewal has not been carried out. Transitional Article 15 postponed the application of this rule until 1 July 2025, and it has applied since then.

Under Article 21 of the Regulation, the MA is renewed five years after the MA date on the basis of a re-evaluation of the benefit/risk balance, and the renewal dossier must be submitted nine months before the five-year period expires. Once renewed, the MA is valid indefinitely unless TİTCK decides on one additional renewal on pharmacovigilance grounds. Under İRD-KLVZ-23, if the MA’s scientific validity period has expired, TİTCK’s confirmation that the MA remains valid is required. This renewal application can be made during the transfer process, but if it is not approved the transfer is not made. The first question for any product planned for transfer is therefore where its renewal timetable stands. We cover this in more detail in MA renewal and GMP certificate validity.

What happens to open variations during a transfer?

The Regulation on Variations to Authorised Human Medicinal Products excludes MA transfers from its scope (Art. 2/2). A transfer is not a variation but a separate procedure governed by the MA Regulation.

In transfers made before a notary, the transferee submits an undertaking that no changes are made to the product during the transfer application (Art. 26/2-a). As a rule, dossier updates and the correction of deficiencies are made after the transfer is completed, in line with the relevant guidelines, and no sales authorisation application can be made until these updates are approved. Where it considers it necessary, TİTCK may ask for the update application earlier (Art. 26/2-b).

TİTCK’s position is clear: according to its FAQ, all variations relating to the product are expected to be concluded before the MA transfer. For updates found to be needed after the transfer application, transfer-specific application types are used at TİTCK’s request: “MA Transfer (Administrative) Type IA/IB” for administrative matters, “MA Transfer (Quality) Type II” for quality matters and “MA Transfer (SmPC/PIL) Type IB/Type II” for the SmPC and PIL. Administrative and SmPC/PIL applications can only be made after TİTCK’s official letter.

İRD-KLVZ-23 also spells out the effect on the timetable: if the assessment shows that the necessary updates have not been made to the dossier, the transfer application is assessed only after the required variations have been submitted and approved. For this reason, the Guideline stresses that the transferee should receive the full and complete MA dossier before the transfer agreements are concluded.

How long are the assessment periods?

  • Transfer application: TİTCK assesses the transfer application within 30 days (Art. 26/4). If dossier updates are missing, this assessment waits until the related variations are approved.
  • Requests for further information: If the information and documents requested by TİTCK, or a statement of when they will be submitted, are not provided within 30 days at the latest, the transfer application is cancelled and the dossier is returned (Art. 26/5).
  • Sales authorisation: After the transfer, a sales authorisation must be obtained from TİTCK before the product is placed on the market (Art. 28/4).
  • Post-transfer variations: Under the Variations Regulation, Type IA and Type IB notifications have a 30-day assessment period and Type II applications 60 days. For Type II this can extend to 90 days in some cases, and the clock stops when further information is requested (Art. 8–10).

These are TİTCK’s assessment periods. With document preparation, deficiency letters and post-transfer updates, the overall timeline can be considerably longer.

How are old-barcode products and bridging stock managed after the transfer?

One of the most common questions is how supply continuity is maintained while the product moves to the new MAH. For transfers made before a notary, the Regulation provides a transition period (Art. 26/2-c):

  • On request, and with a written, notarised agreement between the transferor and the transferee, products with the old barcode may be manufactured for one year from the date the new MA is issued.
  • Only the transferee may place these products on the market. Production notifications are checked through the Pharmaceutical Track and Trace System (İTS).
  • These products may remain on the market until their expiry date.
  • For imported products, the transferor’s supply to the market stops. Under the same agreement, the transferor may import old-barcode products for one year; these may be placed on the market only if the transferor makes the production notification in İTS and transfers the products to the transferee through İTS.

This period used to be six months and was extended to one year by the amendment of 3 December 2024. For comparison, the Variations Regulation still allows six months for old-barcode products where a variation leads to a barcode change (Art. 19). According to TİTCK’s FAQ, an application is made to the İTS Unit for placing old-barcode products on the market.

The transition right is defined in the legislation in terms of “old-barcode products”. The Guideline on the Labelling and Package Leaflets (İRD-KLVZ-07) does not set a separate packaging or PIL transition period specific to transfers. The transfer application itself requires inner and outer packaging drafts for all pack sizes and barcodes registered to the transferee’s name and address.

What to watch in a transfer

  • Renewal status: An MA whose renewal is not complete cannot be transferred. The renewal timetable directly sets the transfer timetable.
  • Document validity: The GMP certificate and the active substance Manufacturing Site Authorisation are critical both for the transfer application and for avoiding suspension of the MA.
  • Dossier status: Whether the dossier handed over is TİTCK-approved and up to date determines the post-transfer update workload.
  • Open applications: TİTCK expects all variations relating to the product to be concluded before the transfer.
  • Obstacles: An attachment on the product, or the transferee already holding an MA for the same strength, form and indication, stops the transfer.
  • Transferee’s set-up: The pharmacovigilance officer, scientific service and İTS records should be ready at the same time as the transfer.
  • Transition period: The one-year right for old-barcode products depends on a notarised agreement between the parties. Without it, the transition right cannot be used.
  • Fees: Under İRD-KLVZ-23, a transfer involves three separate items: the application fee paid with the transfer application, the MA fee set each year by the Ministry of Treasury and Finance, and the MA certificate fee paid once the documents are complete. Transfer variations requested by TİTCK and procedures such as the sales authorisation are also subject to the relevant tariff items.

Sources: Regulation on the Marketing Authorisation of Human Medicinal Products (Official Gazette 11.12.2021/31686; current text as amended on 24.9.2022/31963, 27.5.2023/32203, 26.12.2023/32411 and 3.12.2024/32741), Articles 21, 22, 23, 26, 27, 28, 38 and Transitional Article 15; Regulation on Variations to Authorised Human Medicinal Products (Official Gazette 18.12.2021; current text), Articles 2, 8, 9, 10 and 19; TİTCK Guideline on Cases Requiring the Re-issue of a Marketing Authorisation for Authorised Human Medicinal Products (İRD-KLVZ-23), Rev. 3, 11.08.2026, Articles 5 and 8; TİTCK Guideline on the Labelling and Package Leaflets of Human Medicinal Products (İRD-KLVZ-07), Rev. 18, 11.08.2026; TİTCK FAQ on marketing authorisation procedures (16.02.2024). This article is for general information; current legislation and TİTCK announcements prevail.